A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
Public ClinicalTrials.gov record NCT06022029. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Dose-Escalation and Expansion Study of Intratumorally Administered ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas
Study identification
- NCT ID
- NCT06022029
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- OncoNano Medicine, Inc.
- Industry
- Enrollment
- 168 participants
Conditions and interventions
Conditions
Interventions
- Cemiplimab Drug
- ONM-501 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 12, 2023
- Primary completion
- Apr 29, 2026
- Completion
- Aug 28, 2026
- Last update posted
- Dec 23, 2025
2023 – 2026
United States locations
- U.S. sites
- 9
- U.S. states
- 6
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| California Research Institute | Los Angeles | California | 90027 | Active, not recruiting |
| BRCR Global | Tamarac | Florida | 33321 | Withdrawn |
| Gabrail Cancer Center Research | Canton | Ohio | 44718 | Completed |
| Ohio State University | Columbus | Ohio | 43210 | Completed |
| Allegheny Health Network | Pittsburgh | Pennsylvania | 15224 | Completed |
| UPMC Hillman Cancer Center | Pittsburgh | Pennsylvania | 15232 | Completed |
| University of Texas Southwestern Medical Center | Dallas | Texas | 75390 | Completed |
| MD Anderson Cancer Center | Houston | Texas | 77030 | Active, not recruiting |
| Virginia Cancer Specialists, PC | Fairfax | Virginia | 22031 | Completed |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 7 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06022029, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 23, 2025 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06022029 live on ClinicalTrials.gov.